Checkpoint inhibitor–induced hematologic immune-related adverse events and their association with disease recurrence in hematolymphoid malignancies: a clinical perspective
Blood Research · 2026-12 · 61 (1)
DOI: 10.1007/s44313-026-00135-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood Research, online erschienen am 06.05.2026. Verfasst von Chokri Ben Lamine und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Stem Cell Transplantation and Cellular Therapy, King Faisal Specialist Hospital and Research Centre, Cancer Centre of Excel…. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Immune checkpoint inhibitors have transformed the treatment of hematolymphoid malignancies by enhancing antitumor immunity. These agents are associated with immune-related adverse events (irAEs), including hematologic toxicities such as autoimmune hemolytic anemia, immune-related thrombocytopenia (irTCP), and neutropenia. Although rare, hematologic irAEs (hem-irAEs) may reflect systemic immune activation and could serve as biomarkers of treatment response. Emerging evidence, particularly from observational studies and meta-analyses, suggests that patients who experience hem-irAEs may have lower rates of disease recurrence and improved survival outcomes. This manuscript reviews the mechanisms, incidence, and prognostic implications of hem-irAEs in patients with hematolymphoid malignancies, emphasizing their hypothesis-generating potential as predictive markers that warrant prospective validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Stem Cell Transplantation and Cellular Therapy, King Faisal Specialist Hospital and Research Centre, Cancer Centre of Excellence, Riyadh, Saudi Arabia. benlamine.chokri@gmail.com.
- Alfaisal University, Riyadh, Saudi Arabia. benlamine.chokri@gmail.com.
- Department of Hematology, Stem Cell Transplantation and Cellular Therapy, King Faisal Specialist Hospital and Research Centre, Cancer Centre of Excellence, Riyadh, Saudi Arabia.
- Alfaisal University, Riyadh, Saudi Arabia.
- Internal Medicine Department/Hematology Center, Ain Shams University, Cairo, Egypt.
- Adult Hematology Consultant, SMC Hospitals, Riyadh, Saudi Arabia.
Zitieren
APA
Ben Lamine, C., Hanbali, A., ElGohary, G., Alkhaldi, H., El Fakih, R., & Aljurf, M. (2026). Checkpoint inhibitor–induced hematologic immune-related adverse events and their association with disease recurrence in hematolymphoid malignancies: a clinical perspective. Blood Research, 61(1). https://doi.org/10.1007/s44313-026-00135-4
Vancouver
Ben Lamine C, Hanbali A, ElGohary G, Alkhaldi H, El Fakih R, Aljurf M. Checkpoint inhibitor–induced hematologic immune-related adverse events and their association with disease recurrence in hematolymphoid malignancies: a clinical perspective. Blood Research. 2026;61(1). doi:10.1007/s44313-026-00135-4
BibTeX
@article{BenLamine2026,
author = {Ben Lamine, Chokri and Hanbali, Amr and ElGohary, Ghada and Alkhaldi, Hanan and El Fakih, Riad and Aljurf, Mahmoud},
title = {Checkpoint inhibitor–induced hematologic immune-related adverse events and their association with disease recurrence in hematolymphoid malignancies: a clinical perspective},
journal = {Blood Research},
year = {2026},
volume = {61},
number = {1},
doi = {10.1007/s44313-026-00135-4}
}
EUVIMED